Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
eNq1mF1v2jAUhu/5FVEudkcChVDYEqqNtRtSqzEK2rQbZJJDMQt26g8++uvnELrC5KirwZexndfHPsePXzm82ixTZwWMY0oit+7VXAdITBNMHiJ3PLqptt2rbiVcoBU6GHbp1bz6hevEKeI8cvNebwqIcO/n3e1nUP8Dc7sVJ6TTBcTiaJwUOPW+Ij6/Q1k+xglXFCfOEsScJpGbSbFrdUIumIqiu6bsN89QDKG/bznsXUyah+2hn4v9h6rkwG4RedCKAjHSjCVjQEQPCXigbFsSb8NIG/MhcCpZDAMk5gNGVziBRDvFDKUcjCaZrZN7YKsURD6JVtxfxEtuJI4WaDOEx74+6I+qtyc2olqr1i9bzU7QCFqti8Bss9jBVumzoBbhx5N6I+hcNgMfiL/c0qftEgxzM6BMoNRSVjDvHReWpXkYPL6a/QTzLEVbb8Ez061CDKluYOr421tIvoIRU0BK1Z79o09kmvpvjHq8x4WliHMa9agkooQaN0PTjehRImBTnlEz0InNvhYx8PPJPlGih/xATlMcmyJNQUcCF+Nhv5xo54TBJ8RhzOzR4AcmCV3z81PmMKuWos92oNSKZiypTy467VY9CIwP0S9VQiU3zLVkNANf8QfzU7DSJzN6KlBUVeqlnmvybOW48zk0RimUOJ2qIVtUHT4bM2uVbu8UFR1a0S/XI9Py+C6Bbe93n1ppnER/E2sGXhs0V8X4WuDFsY2ySaMWtDuN5ju0zD48W+jI0C4XolbcsmR6xsyFyPh731+v194c8SpHaj+9GSu/A660Sz/H8hVwX7Jpz9BbMQCFISpgayn0aXGLvi2Npgf3NYtwqu3d/7+319o5BJNwQi4Kxlsjcf/6/HB/8bzWwh4cIcbeNDt/igSmxJZvklOt4mnXicoruWEKEN9mM1zywFJal6FfPO50K6GfP+x0K38AldUBOA==
PX3rFRx961Jc56Ab
Listen
